GlassScriptPhysician profile
Baris Vefali
NPI 1922673656
$5,204.80
in general payments reported to CMS, 2019-2025
15 companies · $2,769 in 2025
The $2,769 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $461 · 2023: $1,221 · 2024: $754 · 2025: $2,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,047 · Travel and Lodging: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,046.79 |
| Travel and Lodging | $696.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,479.94 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Penumbra, INC. | $1,362.37 | 2025 | Indigo System, Penumbra System |
| Shockwave Medical, INC | $580.12 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $511.38 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.99 | 2022-2023 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $280.57 | 2024-2025 | |
| Novo Nordisk INC | $215.09 | 2025 | Ozempic |
| Corcept Therapeutics | $120.13 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $96.16 | 2025 | Rexulti |
| Pfizer INC. | $39.87 | 2024-2025 | |
| Gilead Sciences, INC. | $21.82 | 2024 | Descovy |
| United Therapeutics Corporation | $16.98 | 2024 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $15.71 | 2024 | Fasenra |
| Genzyme Corporation | $15.69 | 2024 | |
| Irhythm Technologies, INC. | $13.98 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baris Vefali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.